Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2019-01-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
第六届监事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed by the Supervisory Board (监事会) of 华兰生物工程股份有限公司 regarding the initial grant of restricted stock to incentive recipients. It includes details about the meeting date, attendance, voting results, and confirmation that the incentive recipients meet legal and regulatory requirements. The document is short (973 characters) and serves as a formal announcement of a board decision related to equity incentive plans. It does not contain financial statements, audit information, or detailed financial data. It is not a full report but a corporate governance-related announcement about management decisions on stock incentives. Therefore, it fits best under Board/Management Information (MANG).
2019-01-17 Chinese
独立董事关于向激励对象首次授予限制性股票的独立意见
Governance Information Classification · 95% confidence The document is a formal independent director opinion regarding the initial grant of restricted shares under a stock incentive plan. It references regulatory guidelines and company rules related to stock incentives and confirms the grant date and number of shares. The content is a formal opinion or statement related to governance and compliance with stock incentive regulations, not a full financial report or earnings release. It is not an announcement of voting results, nor a management report or audit. It fits best under Governance Information (CGR) as it deals with internal governance matters and compliance with stock incentive regulations.
2019-01-17 Chinese
2018年限制性股票激励计划首次授予部分激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as a list of recipients for a 2018 restricted stock incentive plan from 华兰生物工程股份有限公司 (Hualan Biological Engineering Inc.). It details the allocation of restricted stock to management and core technical personnel, including names, positions, and stock quantities. The document is a formal announcement from the company's board dated January 18, 2019. It does not contain financial statements, audit opinions, or regulatory certifications. It is not a report of voting results or a proxy solicitation. The content focuses on management stock incentives, which is related to remuneration and compensation information. Given the detailed listing of stock incentives to executives and key personnel, this fits best under Remuneration Information (DEF 14A), which covers executive and director compensation disclosures including stock incentive plans.
2019-01-17 Chinese
第六届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution regarding the initial grant of restricted stock to incentive recipients. It details the voting results and references compliance with relevant laws and company plans. The content focuses on a board decision about stock incentives, not a full report or financial statement. It is not an annual report, earnings release, or regulatory filing of financial data. The document is a formal announcement of a board/management decision related to stock incentives, fitting the category of Board/Management Information (MANG). The document length is short and it is a meeting resolution announcement, not a report or presentation.
2019-01-17 Chinese
安徽承义律师事务所关于公司2018年限制性股票激励计划首次授予事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2018 restricted stock incentive plan and its initial grant. It discusses the approval, authorization, and compliance with relevant laws and regulations for the stock incentive plan. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital/financing activity (stock incentive plan). It is not a simple announcement but a detailed legal opinion on the stock grant. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3626 characters, which is relatively short but contains substantive legal analysis rather than just an announcement or certification, so it is not RPA or RNS.
2019-01-17 Chinese
关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted shares under a stock incentive plan by 华兰生物工程股份有限公司. It includes specifics about the number of shares granted, the recipients, the conditions for the grant, performance targets, and legal and supervisory approvals. The document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital/financing event related to the issuance of restricted stock to employees and management. This fits the category of Capital/Financing Update (CAP) as it concerns the issuance of new shares under an incentive plan.
2019-01-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.